Verrica Pharmaceuticals (FRA:1NE) Interest Expense : €-5.80 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Verrica Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € -2.13 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-5.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Verrica Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € -17.11 Mil. Verrica Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € -2.13 Mil. Verrica Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Verrica Pharmaceuticals Interest Expense Historical Data

The historical data trend for Verrica Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Interest Expense Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.49

-3.80

-2.05

-3.63

Verrica Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-1.55	-2.11	-2.13

Verrica Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.80 Mil.

Verrica Pharmaceuticals (FRA:1NE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Verrica Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €-2.13 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-17.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €41.80 Mil.

Verrica Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Verrica Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Verrica Pharmaceuticals (FRA:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

VRCA:USA 1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines